IN2014CN03921A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03921A
IN2014CN03921A IN3921CHN2014A IN2014CN03921A IN 2014CN03921 A IN2014CN03921 A IN 2014CN03921A IN 3921CHN2014 A IN3921CHN2014 A IN 3921CHN2014A IN 2014CN03921 A IN2014CN03921 A IN 2014CN03921A
Authority
IN
India
Prior art keywords
sirnas
modified
relates
sirna
guanidinopropyl
Prior art date
Application number
Other languages
English (en)
Inventor
Patrick Arbuthnot
Justin Hean
Abdullah Ely
Musa Marimani
Jolanta Brzezinska
Jennifer DONOFRIO
Maximilian C R Buff
Joachim W Engels
Stefan Bernhardt
Original Assignee
Univ Witwatersrand Jhb
Goethe University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Witwatersrand Jhb, Goethe University filed Critical Univ Witwatersrand Jhb
Publication of IN2014CN03921A publication Critical patent/IN2014CN03921A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3921CHN2014 2011-10-28 2012-10-26 IN2014CN03921A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA201107890 2011-10-28
PCT/IB2012/055915 WO2013061295A1 (fr) 2011-10-28 2012-10-26 Inhibition d'expression génique virale

Publications (1)

Publication Number Publication Date
IN2014CN03921A true IN2014CN03921A (fr) 2015-09-04

Family

ID=47326248

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3921CHN2014 IN2014CN03921A (fr) 2011-10-28 2012-10-26

Country Status (9)

Country Link
US (1) US20140350080A1 (fr)
EP (1) EP2771466A1 (fr)
CN (1) CN104011209A (fr)
AP (1) AP2014007650A0 (fr)
BR (1) BR112014010134A2 (fr)
CA (1) CA2853609A1 (fr)
IN (1) IN2014CN03921A (fr)
RU (1) RU2014121304A (fr)
WO (1) WO2013061295A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014007620A2 (fr) 2012-07-03 2014-01-09 Prosensa Technologies B.V. Oligonucléotide pour le traitement de patients atteints de dystrophie musculaire
WO2016206626A1 (fr) * 2015-06-26 2016-12-29 苏州瑞博生物技术有限公司 Arnsi, composition pharmaceutique et conjugué contenant un arnsi, et utilisations de ces derniers
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
EP3325097B1 (fr) 2015-07-17 2021-09-01 Arcturus Therapeutics, Inc. Compositions et agents contre le virus de l'hépatite b et utilisations de ceux-ci
WO2018230624A1 (fr) * 2017-06-16 2018-12-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composé monomère d'acide nucléique modifié et analogue d'acide oligonucléique
WO2020087107A1 (fr) * 2018-10-31 2020-05-07 The University Of Sydney Compositions et méthodes de traitement d'infections virales

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1814614A (zh) * 2005-02-06 2006-08-09 中国人民解放军军事医学科学院毒物药物研究所 核酸、肽核酸衍生物及它们的用途
WO2009038266A1 (fr) * 2007-09-17 2009-03-26 Mogam Biotechnology Research Institute Procédé pour augmenter la stabilité sérique et réduire la réponse immune d'un gène expression régulant négativement l'arnsi de vhb ou vhc

Also Published As

Publication number Publication date
US20140350080A1 (en) 2014-11-27
CN104011209A (zh) 2014-08-27
WO2013061295A1 (fr) 2013-05-02
RU2014121304A (ru) 2015-12-10
BR112014010134A2 (pt) 2019-09-24
CA2853609A1 (fr) 2013-05-02
EP2771466A1 (fr) 2014-09-03
AP2014007650A0 (en) 2014-05-31

Similar Documents

Publication Publication Date Title
AU2018253578A1 (en) RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EA201490993A1 (ru) МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
MX2020011807A (es) Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
MX2018013216A (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
MX2019006413A (es) Composiciones de arni de serpinc1 y metodos de uso de las mismas.
WO2014022739A3 (fr) Agents constitués d'arni modifié
MX2021009118A (es) Composiciones y metodos para inhibir la expresion del gen alas1.
WO2012024170A3 (fr) Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
MX2021015290A (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
IN2014CN03921A (fr)
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
ATE548454T1 (de) Nukleinsäurewirkstoffe zur stilllegung von h19 zwecks behandlung rheumatoider arthritis
EA201301336A1 (ru) Лечение рака комбинацией молекул днк, имитирующих двухнитевые разрывы, и гипертермии
EA201100847A1 (ru) Опосредованное рнк-интерференцией ингибирование экспрессии генов эпителиального натриевого канала (enac) c использованием малой интерферирующей нуклеиновой кислоты (минк)
WO2010111503A3 (fr) Inhibition à médiation par l'interférence arn de l'expression du gène de la chaîne alpha du récepteur à haute affinité pour les ige (fcεr1α) faisant appel à de courts acides nucléiques interférents (ansi)
WO2010107955A3 (fr) Inhibition médiée par arn interférence de l'expression génique de btb et de l'homologie cnc 1, facteur de transcription 1 de fermeture éclair de leucine basique (bach 1), utilisant une liste de séquences d'acide nucléique interférant court (ansi)
EA201171175A1 (ru) Опосредованное phk-интерференцией ингибирование экспрессии гена межклеточной адгезионной молекулы 1 (icam-1) с использованием короткой интерферирующей нуклеиновой кислоты (sihk)
WO2015020993A3 (fr) Compositions d'arni et méthodes de traitement de l'ataxie de friedreich
EA201490160A1 (ru) Конструкции для сайленсинга гена p0 и применение
MX2011007776A (es) Compsiciones y metodos para inhibir la expresion de genes ptp1b.
AU2015262889A8 (en) Small interfering RNA (siRNA) for the therapy of type 2 (ADO2) autosomal dominant osteopetrosis caused by CLCN7 (ADO2 CLCN7-dependent) gene mutation
WO2012131673A3 (fr) Agents de type acides nucléiques inactivant le ccat-1 pour traiter le cancer
PL398796A1 (pl) Zastosowanie czasteczek miRNA oraz antagomiru dla miRNA w diagnostyce, zapobieganiu i leczeniu stwardnienia rozsianego
TW201129365A (en) Compositions and methods for inhibiting expression of IKK2 genes
NZ776080A (en) Modified rnai agents